Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Primary Objectives: Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary Objectives: Part A: Safety and tolerability of SAR445088 in CIDP Immunogenicity of SAR445088 Efficacy of SAR445088 with overlapping SOC (SOC-Treated …

cyclosporine
igiv
polyneuropathy
methotrexate
immune globulin
  • 0 views
  • 19 Aug, 2022
  • 24 locations
Cognition Evolution and MRI Markers in PPMS Patients on 2 Years (PRO-COG)

primary progressive multiple sclerosis (PPMS) as compared with relapsing-remitting MS (RRMS). In PPMS pathological studies have shown the importance of cortical demyelination and meningeal inflammation

Accepts healthy volunteers
  • 0 views
  • 21 Apr, 2022
  • 3 locations
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis (TOTEM-RRMS)

precursors into mature oligodendrocytes in a cuprizone-induced animal model of demyelination. The rare clinical trials on testosterone are mainly exploratory. Here, we sought to demonstrate an effect of

natalizumab
fatigue
relapsing multiple sclerosis
demyelination
depression
  • 25 views
  • 17 Feb, 2022
  • 4 locations
Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Primary Objectives: Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary Objectives: Part A: Safety and tolerability of SAR445088 in CIDP Immunogenicity of SAR445088 Efficacy of SAR445088 with overlapping SOC (SOC-Treated …

cyclosporine
igiv
polyneuropathy
methotrexate
immune globulin
  • 45 views
  • 14 Jul, 2022
  • 29 locations
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

ph20
polyradiculoneuropathy
polyneuropathy
autoimmune disease
  • 26 views
  • 28 Jun, 2022
  • 92 locations
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

igiv
polyradiculoneuropathy
polyneuropathy
corticosteroids
ph20
  • 407 views
  • 30 Jun, 2022
  • 174 locations
Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury

The overall objective is to obtain an initial assessment of the value of using [18F]3F4AP for imaging demyelinating diseases such as traumatic brain injury (TBI), neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD): Aim 1) Assess the safety of [18F]3F4AP in healthy volunteers and subjects with …

Accepts healthy volunteers
neuropsychological assessment
traumatic brain injury
cognitive assessment
mild cognitive impairment
  • 3 views
  • 17 May, 2022
  • 1 location
ACT-01 in Patients With Acute Optic Neuritis (ACUITY)

To evaluate the safety and tolerability of ACT-01 compared to placebo in patients with acute optic neuritis (AON) receiving the standard of care.

  • 1 views
  • 13 Mar, 2022
Application of ihMT MRI in Multiple Sclerosis (ihMTMS)

The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating

demyelination
relapsing multiple sclerosis
brain mri
MRI
disease or disorder
  • 4 views
  • 05 Mar, 2022
  • 1 location
Entire-body PET Scans for Multiple Sclerosis (EPSMS)

To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in

Accepts healthy volunteers
nervous
demyelination
disease or disorder
  • 0 views
  • 22 Apr, 2022
  • 1 location